Dr. Kenneth Lundstrom received his PhD at the University of Helsinki, Finland on Recombinant Expression of Viral Membrane Proteins in Bacteria. His Post-doctoral studies involved PCR and Antisense Technologies at Cetus Corporation in Palo Alto, California. Dr. Lundstrom established “Alphavirus-based Expression of Receptors and Ion Channels at the Glaxo Institute for Molecular Biology in Geneva, Switzerland, then expanded the utilization of Alphavirus Expression Systems to Neuroscience and Gene Therapy at Roche in Basel. He was appointed Scientific Coordinator of a Structural Genomics Network using Bacterial, Yeast, and Alphavirus Vectors for Large-scale Production of Receptors. In 2009 Dr. Lundstrom established PanTherapeutics in Lausanne, Switzerland a cancer gene therapy applying viral vectors.